Show simple item record

Effect of the IL-17F rs763780 Variant on Chronic Lymphocytic Leukemia and Multiple Myeloma Risk in a Turkish Cohort

dc.contributor.authorPEHLİVAN, MUSTAFA
dc.contributor.authorNURSAL, AYŞE FEYDA
dc.contributor.authorKurnaz, Selin
dc.contributor.authorPehlivan, Sacide
dc.date.accessioned2021-03-04T10:46:00Z
dc.date.available2021-03-04T10:46:00Z
dc.date.issued2018
dc.identifier.citationNURSAL A. F. , PEHLİVAN M., Kurnaz S., Pehlivan S., "Effect of the IL-17F rs763780 Variant on Chronic Lymphocytic Leukemia and Multiple Myeloma Risk in a Turkish Cohort", ISTANBUL MEDICAL JOURNAL, cilt.19, sa.1, ss.39-42, 2018
dc.identifier.othervv_1032021
dc.identifier.otherav_6ed6966b-1049-4992-8b86-38f06633b4e3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/76517
dc.identifier.urihttps://doi.org/10.5152/imj.2018.58751
dc.description.abstractIntroduction: Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in developed countries. Multiple myeloma (MM), a clonal plasma cell disease, is the second most prevalent hematological cancer. Interleukin-17 (IL-17) can facilitate the secretion of numerous proinflammatory cytokines. The goal of the present study was to evaluate the effect of IL-17F rs763780 on CLL/MM susceptibility in a Turkish cohort.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectTemel Tıp Bilimleri
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleEffect of the IL-17F rs763780 Variant on Chronic Lymphocytic Leukemia and Multiple Myeloma Risk in a Turkish Cohort
dc.typeMakale
dc.relation.journalISTANBUL MEDICAL JOURNAL
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume19
dc.identifier.issue1
dc.identifier.startpage39
dc.identifier.endpage42
dc.contributor.firstauthorID251922


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record